

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ :
C07D 498/18, C07K 5/06
A61K 31/395, 37/02
// (C07D 498/18, 311/00, 273/00)

A1

(11) International Publication Number: WO 92/05179
(43) International Publication Date: 2 April 1992 (02.04.92)

(21) International Application Number: PCT/US91/06824

(22) International Filing Date: 19 September 1991 (19.09.91)

(30) Priority data:

584,833 19 September 1990 (19.09.90) US
589,878 28 September 1990 (28.09.90) US
657,294 19 February 1991 (19.02.91) US

(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; 685 Third Avenue, New York, NY 10017 (US).

(72) Inventors: CAUFIELD, Craig, Eugene ; 30-08 Raven's Crest Drive, Plainsboro, NJ 08536 (US); FAILLI, Amedeo, Arturo ; 14 Landing Lane, Princeton Junction, NJ 08550 (US); STEFFAN, Robert, John ; 263 Wheat-sheaf Lane, Langhorne, PA 19047 (US).


(74) Agents: ALICE, Ronald, W. et al.; American Home Products Corporation, 685 Third Avenue, New York, NY 10017 (US).

(31) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), SU*.


Published

With international search report.

(54) Title: CARBOXYLIC ACID ESTERS OF RAPAMYCIN







(I)



(d)

(57) Abstract

A compound of structure (I), wherein R¹, R², and R³ are each, independently, hydrogen, or R⁴; R⁴ is (a), (b), or (c); R⁵ is hydrogen, alkyl, aralkyl, -(CH₂)_qCO₂R⁸, -(CH₂)_rNR⁹CO₂R¹⁰, carbamylalkyl, aminoalkyl, hydroxyalkyl, guanlylalkyl, mercaptoalkyl, alkylthioalkyl, indolylmethyl, hydroxyphehylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl, alkoxy, hydroxy, cyano, halo, nitro, carbalkoxy, trifluoromethyl, amino, or a carboxylic acid; R⁶ and R⁹ are each, independently, hydrogen, alkyl, or aralkyl; R⁷, R⁸, and R¹⁰ are each, independently, alkyl, aralkyl, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted; R¹¹ and R¹² are each, independently, alkyl, aralkyl, or phenyl which is optionally mono-, di-, or tri-substituted; X is (d), O, or S; R¹³ and R¹⁴ are each, independently, hydrogen or alkyl; Y is CH or N; m is 0-4; n is 0-4; p is 1-2; q is 0-4; r is 0-4; t is 0-4; u is 0-4; wherein R⁵, R⁶, m, and n are independent in each of (c) subunits when p=2; or a pharmaceutically acceptable salt thereof, with the proviso that R¹, R², and R³ are not all hydrogen, further provided that R¹, R² and R³ are not all (a), and still further provided that t and u are not both 0 when X is O or S, which by virtue of its immuno-suppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation, and by virtue of its antifungal activity is useful in treating fungal infections.



+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CC	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

CARBOXYLIC ACID ESTERS OF RAPAMYCIN

BACKGROUND OF THE INVENTION

5 This invention relates to novel esters of rapamycin and a method for using them in the treatment of transplantation rejection, host vs. graft disease, autoimmune diseases, diseases of inflammation, and fungal infections.

Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces
10 hygroscopicus, which was found to have antifungal activity, particularly against Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Seghal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Patent 3,929,992; and U.S. Patent 3,993,749].

Rapamycin alone (U.S. Patent 4,885,171) or in combination with picibanil
15 (U.S. Patent 4,401,653) has been shown to have antitumor activity. R. Martel et al. [Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the formation of IgE-like antibodies.


The immunosuppressive effects of rapamycin have been disclosed in FASEB 3,
20 3411 (1989), rapamycin has been shown to be effective in inhibiting transplant rejection (U.S. Patent Application Ser. No. 362,544 filed June 6, 1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); and R. Y. Calne et al., Lancet 1183 (1978)].

25 Mono- and diacylated derivatives of rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Patent 4,316,885) and used to make water soluble prodrugs of rapamycin (U.S. Patent 4,650,803). Recently, the numbering convention for rapamycin has been changed; therefore according to Chemical Abstracts nomenclature, the esters described above would be at
30 the 31- and 42- positions.


- 2 -

DESCRIPTION OF THE INVENTION

This invention provides derivatives of rapamycin which are useful as immunosuppressive, anti-inflammatory, and antifungal agents having the structure



wherein R^1 , R^2 , and R^3 are each, independently, hydrogen, or R^4 ;



R^5 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, $-(CH_2)_qCO_2R^8$, $-(CH_2)_rNR^9CO_2R^{10}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanyalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

R^6 and R^9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;

- 3 -

R⁷, R⁸, and R¹⁰ are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

R¹¹ and R¹² are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

X is $\begin{array}{c} \text{R}^{13} \\ | \\ -\text{C}- \\ | \\ \text{R}^{14} \end{array}$, O, or S;

R¹³ and R¹⁴ are each, independently, hydrogen or alkyl of 1-6 carbon atoms;

Y is CH or N;

m is 0 - 4;

n is 0 - 4;

p is 1 - 2;

q is 0 - 4;

r is 0 - 4;

t is 0 - 4;

u is 0 - 4;

wherein R⁵, R⁶, m, and n are independent in each of the $\begin{array}{c} \text{O} \\ || \\ \text{[C(CH}_2\text{)}_m\text{CH(CH}_2\text{)}_n\text{N]} \\ | \quad | \\ \text{R}^5 \quad \text{R}^6 \end{array}$


subunits when p = 2;

or a pharmaceutically acceptable salt thereof, with the proviso that R¹, R², and R³ are not all hydrogen, further provided that R¹, R², and R³ are not all


$\begin{array}{c} \text{O} \\ || \\ -\text{[C(CH}_2\text{)}_m\text{CH(CH}_2\text{)}_n\text{N]}_p\text{CO}_2\text{R}^7 \\ | \quad | \\ \text{R}^5 \quad \text{R}^6 \end{array}$, and still further provided that t and u are not

both 0 when X is O or S.

- 4 -





preferred members are those in which $m = 0$, $n = 0$, and $p = 1$; $m = 0$, $n = 0$, and $p = 2$; $n = 0$, and R^5 is $-(\text{CH}_2)_q\text{CO}_2\text{R}^8$; $m = 0$, $n = 0$, and R^5 is $-(\text{CH}_2)_r\text{NR}^9\text{CO}_2\text{R}^{10}$; and $m = 0$, $n = 0$, and R^5 is hydrogen. Preferred compounds also include those



The pharmaceutically acceptable salts may be formed from inorganic cations such as sodium, potassium, and the like; mono-, di-, and trialkyl amines of 1-6 carbon atoms, per alkyl group and mono-, di-, and trihydroxyalkyl amines of 1-6 carbon atoms per alkyl group; and organic acids such as acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, and the like. Preferred basic salts are formed from sodium cations and tris(hydroxymethyl)methylamine.

The compounds of this invention can be prepared by acylating rapamycin with an acylating agent having the general structures



15 where Z is OH in the presence of a coupling reagent, such as dicyclohexylcarbodiimide. The compounds of this invention also can be prepared using an anhydride or a mixed anhydride of the above described carboxylic acid as the acylating species. Alternatively, the acylating species can be an acid halide, where Z can be Cl, Br, or I. The acylating groups used to prepare the compounds of this invention are commercially available or can be prepared by methods that are disclosed in the literature.

20 Where it is desired to prepare acyl derivatives having two or three different R^4 groups then sequential acylation may be performed using appropriate acylating agents as defined above, if necessary isolating the desired product by appropriate purification

- 5 -

techniques. In general the 42-position is acylated first and such a monoacylated product may be isolated prior to the second acylation and so forth. Appropriate protecting groups may be used to block any position where acylation is not required.

5 Immunosuppressive activity was evaluated in an in vitro standard pharmacological test procedure to measure lymphocyte proliferation (LAF) and in two in vivo standard pharmacological test procedures. The first in vivo procedure was a popliteal lymph node (PLN) test procedure which measured the effect of compounds of this invention on a mixed lymphocyte reaction and the second in vivo procedure evaluated the survival time of a pinch skin graft.

10 The mitogen-induced thymocyte proliferation procedure (LAF) was used as an in vitro measure of the immunosuppressive effects of representative compounds. Briefly, cells from the thymus of normal BALB/c mice are cultured for 72 hours with PHA and IL-1 and pulsed with tritiated thymidine during the last six hours. Cells are cultured with and without various concentrations of rapamycin, cyclosporin A, or test
15 compound. Cells are harvested and incorporated; radioactivity is determined. Inhibition of lymphoproliferation is assessed in percent change in counts per minute from non-drug treated controls. The results are expressed by the following ratio, or as the percent inhibition of lymphoproliferation of 1 μ M.

20
$$\frac{{}^3\text{H-control thymus cells} - {}^3\text{H-rapamycin-treated thymus cells}}{{}^3\text{H-control thymus cells} - {}^3\text{H-test compound-treated cells}}$$

A mixed lymphocyte reaction (MLR) occurs when lymphoid cells from genetically distinct animals are combined in tissue culture. Each stimulates the other to
25 undergo blast transformation which results in increased DNA synthesis that can be quantified by the incorporation of tritiated thymidine. Since stimulating a MLR is a function of disparity at Major Histocompatibility antigens, an in vivo popliteal lymph node (PLN) test procedure closely correlates to host vs. graft disease. Briefly, irradiated spleen cells from BALB/c donors are injected into the right hind foot pad of
30 recipient C3H mice. The drug is given daily, p.o. from Day 0 to Day 4. On Day 3 and Day 4, tritiated thymidine is given i.p., b.i.d. On Day 5, the hind popliteal lymph nodes are removed and dissolved, and radioactivity counted. The corresponding left PLN serves as the control for the PLN from the injected hind foot. Percent suppression is calculated using the non-drug treated animals as allogenic control.
35 Rapamycin at a dose of 6 mg/kg, p.o. gave 86% suppression, whereas cyclosporin A at the same dose gave 43% suppression. Results are expressed by the following ratio:

³H-PLN cells control C3H mouse - ³H-PLN cells rapamycin-treated C3H mouse
³H-PLN cells control C3H mouse - ³H-PLN cells test compound-treated C3H mouse

- 5 The second *in vivo* test procedure is designed to determine the survival time of
 pinch skin graft from male DBA/2 donors transplanted to male BALB/c recipients. The
 method is adapted from Billingham R.E. and Medawar P.B., J. Exp. Biol. 28:335-
 402, (1951). Briefly, a pinch skin graft from the donor is grafted on the dorsum of the
 recipient as a homograft, and an autograft is used as control in the same region. The
 10 recipients are treated with either varying concentrations of cyclosporin A as test control
 or the test compound, intraperitoneally. Untreated recipients serve as rejection control.
 The graft is monitored daily and observations are recorded until the graft becomes dry
 and forms a blackened scab. This is considered as the rejection day. The mean graft
 survival time (number of days \pm S.D.) of the drug treatment group is compared with
 15 the control group.

The following table summarizes the results of representative compounds of this
 invention in these three standard test procedures.

TABLE 1

20

Compound	LAF* (ratio)	PLN* (ratio)	Skin Graft (days \pm S.D.)
Example 1	1.8	0.61	12.0 \pm 1.6
Example 2	0.33	0.62	11.5 \pm 0.6
25 Example 3	0.20	+	9.0 \pm 0.9
Example 4	4.9	0.18	12.3 \pm 0.5
Example 5	0.006	+	8.8 \pm 0.9
Example 6	5.4	0.33	11.5 \pm 3.5
Example 7	3% at 1 μ M**	+	7.7 \pm 1.5
30 Example 8	0.03	0.41	+
Example 9	0.96	1.34	10.3 \pm 0.8
Example 10	2.0	0.96 ⁺⁺	12.7 \pm 1.2
Example 11	0.004	+	10.5 \pm 1.3
Example 12	19.8	-2.87	12.0 \pm 2.0
35 Example 13	22% at 1 μ M**	+	7.0 \pm 0.6
Example 14	0.37	+	8.2 \pm 1.2
Example 15	0.9	0.69	10.7 \pm 1.2

- 7 -

TABLE 1 (Continued)

	<u>Compound</u>	<u>LAF*</u> (ratio)	<u>PLN*</u> (ratio)	<u>Skin Graft</u> (days + SD)
5	Example 16	3.27	1.04##	12.7 ± 0.9
	Example 17	0.56	1.68###	10.2 ± 1.7
	Example 18	0.02	1.11##	8.0 ± 1.7
	Example 19	0.01	0.48	8.0 ± 0.9
	Example 20	0.97	0.70	9.3 ± 1.6
10	Example 21	0.22	-1.93	12.0 ± 1.7
	Example 22	0.22	0.41	10.2 ± 1.2
	Example 23	0.18	0.39	10.8 ± 0.8
	Example 24	0.00	0.09	7.8 ± 1.7
	Rapamycin	1.0	1.0	12.0 ± 1.7

15

* Calculation of ratios was described supra.

** Result expressed as percent inhibition of lymphoproliferation at 1 µM.

+ Not evaluated

++ Results obtained using cremophore/ethanol as a vehicle for administration.

20

Ratios of 0.33 and 1.07 were also obtained using carboxymethyl cellulose as a vehicle for administration.

Results obtained using cremophore/ethanol as a vehicle for administration.

Ratios of 0.20 and 1.08 also were obtained using carboxymethyl cellulose as a vehicle for administration.

25

A ratio of 0.42 also was obtained for this compound.

The results of these standard pharmacological test procedures demonstrate immunosuppressive activity both in vitro and in vivo for the compounds of this invention. Positive ratios in the LAF and PLN test procedures indicate suppression of T cell proliferation. As a transplanted pinch skin grafts are typically rejected within 6-7 days without the use of an immunosuppressive agent, the increased survival time of the skin graft when treated with the compounds of this invention further demonstrates their utility as immunosuppressive agents. While it appears that the compound disclosed by Examples 12 and 21 may cause T cell proliferation in the PLN test procedure, it is believed a negative ratio in this test procedure coupled with an increased survival time observed in the skin graft test procedure indicates a proliferation of T_{suppressor} cells,

- 8 -

which are implicated in suppressing the immune response. (see, I. Roitt et al. Immunology, C.V.Moseby Co. 1989, p 12.8-12.11).

Antifungal activity of the compounds of this invention was measured against 5 strains of Candida albicans using a plate test procedure for measurement of inhibition. The following represents the typical procedure used. Compound to be tested was placed on sterile dried 1/4" plate disks, and allowed to dry. Agar plates were seeded with fungi and allowed to solidify. The impregnated disks were placed on the seeded Agar surface and incubated for the time required for the particular culture. Results are expressed in MIC ($\mu\text{g/ml}$) to inhibit growth. The results of this test procedure showed that the compounds of this invention have antifungal activity; however, it was surprising that the compounds of this invention were less active than the parent compound, rapamycin.

Table 2*

		Strain of <i>Candida albicans</i>					
		<u>Compound</u>	<u>ATCC 10231</u>	<u>ATCC 38246</u>	<u>ATCC 38247</u>	<u>ATCC 38248</u>	<u>3659</u>
20	Example 1	> 0.4	> 0.4	> 0.4	>0.4	>0.4	
	Example 2	0.1	0.2	0.2	0.2	0.1	
	Example 3	0.4	> 0.4	> 0.4	>0.4	0.4	
	Example 4	0.1	0.4	0.1	0.1	0.2	
	Example 5	> 0.4	> 0.4	> 0.4	>0.4	>0.4	
25	Example 6	0.1	> 0.4	0.2	0.4	>0.4	
	Example 7	+	+	+	+	+	
	Example 8	> 0.4	> 0.4	> 0.4	>0.4	>0.4	
	Example 9	0.4	> 0.4	0.4	>0.4	>0.4	
	Example 10	0.2	> 0.4	0.2	0.4	0.4	
30	Example 11	> 0.4	> 0.4	> 0.4	>0.4	>0.4	
	Example 12	0.2	> 0.4	0.1	0.2	0.4	
	Example 13	> 0.4	> 0.4	> 0.4	>0.4	>0.4	
	Example 14	> 0.4	> 0.4	> 0.4	>0.4	>0.4	
	Example 15	> 0.4	0.4	> 0.4	0.4	0.4	
35	Example 16	0.2	0.1	0.4	0.1	0.1	
	Example 17	> 0.4	0.2	> 0.4	0.2	0.4	
	Example 18	0.4	> 0.4	> 0.4	>0.4	>0.4	
	Example 19	0.4	> 0.4	0.4	>0.4	>0.4	

- 9 -

Table 2* (Continued)
Strain of *Candida albicans*

Compound	ATCC 10231	ATCC 38246	ATCC 38247	ATCC 38248	3669
Example 20	0.1	0.4	0.1	0.1	0.2
5 Example 21	0.4	> 0.4	0.4	>0.4	>0.4
Example 22	0.2	> 0.4	0.2	0.4	>0.4
Example 23	0.1	> 0.4	0.2	0.4	>0.4
Example 24	> 0.4	> 0.4	>0.4	>0.4	>0.4
10 Rapamycin	0.003	0.025	0.003	0.006	0.025

* expressed as MIC ($\mu\text{g/ml}$)

+ not evaluated

Based on the results of these standard pharmacological test procedures, the compounds are useful in the treatment of transplantation rejection such as, heart, kidney, liver, bone marrow, and skin transplants; autoimmune diseases such as, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, and multiple sclerosis; and diseases of inflammation such as, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease; and fungal infections.

The compounds may be administered neat or with a pharmaceutical carrier to a mammal in need thereof. The pharmaceutical carrier may be solid or liquid.

A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier

- 10 -

can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially
5 containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful
10 in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous
15 injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form.

Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be
20 packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The dosage to be used in the treatment must be subjectively determined by the attending physician.

25 In addition, the compounds of this invention may be employed as a solution, cream, or lotion by formulation with pharmaceutically acceptable vehicles containing 0.1- 5 percent, preferably 2%, of active compound which may be administered to a fungally affected area.

30

The following examples illustrate the preparation of representative compounds of this invention.

Example 1Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine

5 Under anhydrous conditions, a solution of rapamycin (3 g, 3.28 mmole) and N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine (3.04 g, 13.1 mmole) in 40 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.35 g, 6.56 mmole) followed by 4-dimethylaminopyridine (0.8 g, 6.56 mmole). After stirring at ambient temperature for 48 hours, the precipitated solid was collected and washed with
10 dichloromethane. The combined filtrates were absorbed directly onto silica gel Merck 60 by adding the gel and evaporation to dryness. Flash chromatography of the preabsorbed material (using a gradient elution with ethylacetate-toluene from 2:1 to 1:0 v/v) afforded 1.05 g (28.3 %) of the title compound isolated as a three quarter toluene solvate, along with the 31,42-diester of Example 2. HPLC analysis showed that the
15 monocester is a 8.3:1 mixture of two conformers.

^1H NMR (CDCl_3 , 400 MHz): δ 1.46 (m, 9H, COO^tBu), 1.654 (s, 3H, $\text{CH}_3\text{C}=\text{C}$), 1.751 (s, 3H, $\text{CH}_3\text{C}=\text{C}$), 3.14 (s, 3H, CH_3O), 3.33 (s, 3H, CH_3O), 3.36 (s, 3H, CH_3O), 4.18 (d, 1H, CHOH), 4.75 (m, 1H, 42-CHO), 4.79 (s, 1H, OH); High Res. MS (neg. ion FAB) Calcd for $\text{C}_{60}\text{H}_{93}\text{N}_3\text{O}_{17}$: 1127.6504, measured
20 mass 1127.6474.

Anal. Calcd for $\text{C}_{60}\text{H}_{93}\text{N}_3\text{O}_{17} \cdot 0.75 \text{ PhCH}_3$: C, 65.45; H, 8.33; N, 3.51

Found: C, 65.23; H, 8.32; N, 3.86

25

The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to prepare the title compound in Example 1.

- 30 Rapamycin-42-ester with N-[(fluorenylmethoxy)carbonyl]-alanylserine
Rapamycin-42-ester with N-[(fluorenylmethoxy)carbonyl]-glycylglycine
Rapamycin-42-ester with N-[(ethoxy)carbonyl]-arginylmethionine
Rapamycin-42-ester with N-[(4'-chlorophenoxy)carbonyl]-histidylarginine
Rapamycin-42-ester with N-[(phenoxy)carbonyl]-tryptophanylleucine
35 Rapamycin-42-ester with N-[(phenylmethoxy)carbonyl]-N-methylglycyl-N-ethylalanine

- 12 -

Rapamycin-42-ester with N-[(phenylmethoxy)carbonyl]-N-methyl- β -
alanylphenylalanine

Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-cysteinylglycine

5

Example 2

Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine

10 The title compound (1.85 g, 42%) was separated from the 42-monoester as described in Example 1 and isolated as a three quarter toluene solvate. HPLC analysis showed that the diester is a 8.1:1 mixture of conformers.

^1H NMR (CDCl_3 , 400 MHz): δ 1.452 (m, 18H, COO^tBu), 1.6612 (s, 3H, $\text{CH}_3\text{C}=\text{C}$), 1.7815 (s, 3H, $\text{CH}_3\text{C}=\text{C}$), 3.14 (s, 3H, OCH_3), 3.34 (s, 3H, OCH_3),
15 3.35 (s, 3H, OCH_3), 4.52 (s, 1H, OH), 4.79 (m, 1H, 42-CHO); High Res. MS (neg. ion FAB): Calcd for $\text{C}_{69}\text{H}_{107}\text{N}_5\text{O}_{21}$ 1341.7458, measured mass: 1341.7463.

Anal. Calcd for $\text{C}_{69}\text{H}_{107}\text{N}_5\text{O}_{21} \cdot 0.75 \text{ PhCH}_3$: C, 63.17; H, 8.06; N, 4.96

Found: C, 62.83; H, 8.09; N, 5.00

20

The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to prepare the title compound in Example 2.

- 25 Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-alanylserine
Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-glycylglycine
Rapamycin-31,42-diester with N-[(ethoxy)carbonyl]-arginylmethionine
Rapamycin-31,42-diester with N-[(4'-chlorophenoxy)carbonyl]-histidylarginine
Rapamycin-31,42-diester with N-[(phenoxy)carbonyl]-tryptophanyleucine
30 Rapamycin-31,42-diester with N-[(phenylmethoxy)carbonyl]-N-methylglycyl-N-ethyl-alanine
Rapamycin-31,42-diester with N-[(phenylmethoxy)carbonyl]-N-methyl- β -alanylphenyl-alanine
Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-cysteinylglycine

35

Example 3Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine

5 Under anhydrous conditions, an ice cold solution of rapamycin (2 g, 2.18 mmole) and N^α-Boc sarcosine (1.65 g, 8.75 mmole) in 20 ml of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.8 g, 8.7 mmole) followed by 4-dimethylaminopyridine (1 g, 8.7 mmole). After stirring overnight at ambient temperature, the precipitated solid was collected and washed with
10 dichloromethane. The combined filtrates were evaporated to dryness to give an amorphous amber solid (3 g). The crude product was purified by flash chromatography (on silica Merck 60, elution with hexane-ethylacetate 1:1, v/v) to provide the title compound (0.75 g, 27.4%) along with the 42-monoester of Example 4. HPLC analysis showed that the diester is a 19.8:1 mixture of two conformers. The multiplicity of the
15 NMR peaks suggests the presence of amide rotamers.

¹H NMR (CDCl₃, 400 MHz): δ 1.411, 1.438, 1.448 and 1.474 (m, 18 H, COOBu^t), 2.91 (m, 6H, NCH₃), 3.14 (s, 3H, CH₃O), 3.34 (s, 3H, CH₃O), 3.37 (s, 3H, CH₃O), 4.73 (broad, 1H, 42-CHO), 4.82 (2s, 1H, OH); High Res. MS (neg. ion FAB): Calcd. for C₆₇H₁₀₅N₃O₁₉ 1255.7342, measured mass 1255.7289.

20 Anal. Calcd for C₆₇H₁₀₅N₃O₁₉: C, 64.04; H, 8.42; N, 3.34

Found: C, 64.14; H, 8.74; N, 3.63

The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to
25 prepare the title compound in Example 3.

Rapamycin-31,42-diester with N-[(ethoxy)carbonyl]-tyrosine

Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-phenylalanine

Rapamycin-31,42-diester with N-[(3',4',5'-trihydroxyphenoxy)carbonyl]-isoleucine

30 Rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-glutamine

Rapamycin-31,42-diester with N-[(phenoxy)carbonyl]-N-methylalanine

Rapamycin-31,42-diester with N-[(propyloxy)carbonyl]-4-aminobutyric acid

Rapamycin-31,42-diester with N-[(phenylmethoxy)carbonyl]-7-aminoheptanoic acid

Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]-serine

35

Example 4

Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine

5 Under anhydrous conditions, an ice cold solution of rapamycin (0.95 g, 1.02 mmole) and N^α-Boc sarcosine (0.21 g, 1.1 mmole) in 20 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide 0.21 g, 1 mmole) followed by 4-dimethylaminopyridine (0.12 g, 1 mmole). After stirring for 4 hours at ambient temperature, the precipitated solid was collected and washed with dichloromethane. The
10 combined filtrates were concentrated *in vacuo* to give an amorphous amber solid. Flash chromatography of the crude product (on silica Merck 60, elution with hexane-ethylacetate 1:1 v/v to remove the diester of Example 3, followed by chloroform-ethylacetate-methanol 75:25:1 v/v) provided partially purified title compound (0.38 g, 35%). Pure product was obtained by preparative HPLC (Waters Prep 500, silica gel,
15 chloroform-ethylacetate-methanol 75:25:1 v/v, flow rate 250 mL/min). HPLC analysis showed that the ester is a 6.6:1 mixture of two conformers. The multiplicity of NMR peaks suggests the presence of amide rotamers.

¹H NMR (CDCl₃, 400 MHz): δ 1.42-1.46 (ds, 9H, COOBu^t), 2.91 (ds, 3H, NCH₃), 1.644 (s, 3H, CH₃C=C), 1.738 (s, 3H, CH₃C=C), 3.12 (s, 3H, CH₃O),
20 3.32 (s, 3H, CH₃O), 3.35 (s, 3H, CH₃O), 4.18 (d, 1H, CHO), 4.71 (broad, 1H, 42-CHO), 4.78 (broad s, 1H, OH); High Res. MS (neg. ion FAB): Calcd for C₅₉H₉₂N₂O₁₆ 1084.6446, measured mass 1084.6503.

Anal. Calcd for C₅₉H₉₂N₂O₁₆: C, 65.29; H, 8.54; N, 2.58

Found: C, 65.25; H, 8.52; N, 2.42

25

The following representative compounds can be prepared from rapamycin and the appropriate terminally-N-substituted amino acid by employing the method used to prepare the title compound in Example 4.

- 30 Rapamycin-42-ester with N-[(ethoxy)carbonyl]-tyrosine
Rapamycin-42-ester with N-[(fluorenylmethoxy)carbonyl]-phenylalanine
Rapamycin-42-ester with N-[(3',4',5'-trihydroxyphenoxy)carbonyl]-isoleucine
Rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-glutamine
Rapamycin-42-ester with N-[(phenoxy)carbonyl]-N-methylalanine
35 Rapamycin-42-ester with N-[(propyloxy)carbonyl]-4-aminobutyric acid
Rapamycin-42-ester with N-[(phenylmethoxy)carbonyl]-7-aminoheptanoic acid

- 15 -

Rapamycin-31,42-diester with N-[(fluorenylmethoxy)carbonyl]serine

Example 5

5 Rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-2-[[1,1-dimethylethoxy)-
carbonyl]amino]-5-oxopentanoic acid

Under anhydrous conditions, an ice cold solution of rapamycin (4 g, 4.37 mmole) and L-glutamic acid N^α-Boc-γ-tert-butylester (4.9 g, 16.1 mmole) in 40 mL of dry dichloromethane was treated with dicyclohexylcarbodiimide (1.8 g, 8.7 mmole) followed by 4-dimethylaminopyridine (1 g, 8.7 mmole). After stirring overnight at room temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were concentrated *in vacuo* to provide 11 g of an amorphous amber solid. The crude product was purified by flash chromatography (on silica Merck 60, gradient elution with hexane-ethylacetate from 2:1 to 1:1, v/v) to yield 4.52 g (69.6%) of the title compound along with the 42-monoester of Example 6. HPLC analysis showed that the diester consists of a 6.6:1 mixture of two conformers.

¹H NMR (CDCl₃, 400 MHz): δ 1.42 (m, 36 H, COOBu^t), 1.646 (s, 3H, CH₃C=C), 1.701 (s, 3H, CH₃C=C), 3.13 (s, 3H, CH₃O), 3.34 (s, 3H, CH₃O), 3.36 (s, 3H, CH₃O), 4.735 (m, 2H, OH+42-CH-O); High Res. MS (neg. ion FAB): calc. for C₇₉H₁₂₅N₃O₂₃ 1483.8715, measured mass 1483.8714.

Anal. Calcd for C₇₉H₁₂₅N₃O₂₃: C, 63.90; H, 8.49; N, 2.83

Found: C, 63.63; H, 8.41; N, 2.44

The following representative compounds can be prepared from rapamycin and the appropriately terminally-N-substituted amino diacid monoester by employing the method used to prepare the title compound in Example 5.

30 Rapamycin-31,42-diester with 6-(phenylmethoxy)-2-[[fluorenylmethoxy)carbonyl]-amino]-6-oxohexanoic acid

Rapamycin-31,42-diester with 6-(4'-methylphenoxy)-3-[[phenylmethoxy)carbonyl]-amino-6-oxohexanoic acid

35 Rapamycin-31,42-diester with 6-(ethoxy)-4-[[phenoxy)carbonyl]amino]-6-oxo-hexanoic acid

- 16 -

Rapamycin-31,42-diester with 6-(methoxy)-5-[[ethoxy]carbonyl]amino]-6-oxo-hexanoic acid

Rapamycin-31,42-diester with 4-(phenoxy)-2-[N-[(1,1-dimethylethoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid

- 5 Rapamycin-31,42-diester with 4-(phenylmethoxy)-3-[N-[(methoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid

Example 6

10

Rapamycin-42-ester with 5-(1,1-dimethylethoxy)-2-[[1,1-dimethylethoxy]-carbonyl]amino]-5-oxopentanoic acid

- 15 The title compound (1.14 g, 20.6%) was separated from the 31,42-diester as described in Example 5 and isolated as the quarter hydrate/mono-ethyl acetate solvate. HPLC analysis showed that the monoester is a 11.5:1 mixture of two conformers.

¹H NMR (CDCl₃, 400 MHz): δ 1.425 (m, 18H, COOBu^t), 1.643 (s, 3H, CH₃C=C), 1.737 (s, 3H, CH₃C=C), 3.13 (s, 3H, CH₃O), 3.32 (s, 3H, CH₃O), 3.36 (s, 3H, CH₃O), 4.17 (d, 1H, CHOH), 4.71 (M, 1H, 42-CHO), 4.785 (s, 1H, OH); High Resolution MS (neg. ion FAB): Calc. for C₆₅H₁₀₂N₂O₁₈ 1198.7127, measured mass 1198.7077.

25 Anal. Calcd for C₆₅H₁₀₂N₂O₁₈ · CH₃COOEt · 0.25 H₂O:
C, 64.13, H, 8.60; N, 2.17
Found: C, 64.18; H, 8.52; N, 2.01

- 30 The following representative compounds can be prepared from rapamycin and the appropriately terminally-N-substituted amino diacid monoester by employing the method used to prepare the title compound in Example 6.

Rapamycin-42-ester with 6-(phenylmethoxy)-2-[[fluorenylmethoxy]carbonyl]-amino]-6-oxohexanoic acid

- 35 Rapamycin-42-ester with 6-(4'-methylphenoxy)-3-[[phenylmethoxy]carbonyl]-amino]-6-oxohexanoic acid

- 17 -

Rapamycin-42-ester with 6-(ethoxy)-4-[(phenoxy)carbonyl]amino]-6-oxo- hexanoic acid

Rapamycin-42-ester with 6-(methoxy)-5-[(ethoxy)carbonyl]amino]-6-oxo- hexanoic acid

- 5 Rapamycin-42-ester with 4-(phenoxy)-2-[N-[(1,1-dimethylethoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid

Rapamycin-42-ester with 4-(phenylmethoxy)-3-[N-[(methoxy)carbonyl]-N-methylamino]-4-oxobutanoic acid

10 Example 7

Rapamycin-31,42-diester with 2-[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid

- 15 Under anhydrous conditions, 295mg (1.21mmol) of 2,4,6 trichlorobenzoyl chloride was added to a solution of 391mg(1.21mmol) of N^α-Boc-L-aspartic acid-β-benzyl ester and 170μL (1.21mmol) of Et₃N in 1 mL of THF at room temperature. After stirring for 30 minutes, 500 mg (0.55mmol) of rapamycin and 295 mg (2.42 mmol) of dimethylaminopyridine was added and the reaction was left to stir overnight.
- 20 The reaction mixture was then filtered and the filtrate concentrated *in vacuo*. Pure product (200 mg, 25%) was obtained by preparative HPLC (5 cm column, 40 % ethyl acetate-hexane). The product was isolated as the heptahydrate.

- 25 ¹H NMR (CDCl₃, 400 MHz) δ 7.347 (s, 10 H, Ar), 6.223, 5.126 (s, 4 H, CH₂Ph), 4.698 (m, 1 H, CH-CO₂), 4.587 (m, 2 H, NH), 3.353 (s, 3 H, CH₃O), 3.337 (s, 3 H, CH₃O), 3.301 (s, 3 H, CH₃O), 2.775 (m, 4 H, CH₂CO₂); IR (KBr) 3420 (OH), 2935 (CH), 2920 (CH), 1730 (C=O), 1650, 1500, 1455, 1370, 1170 cm⁻¹; MS (neg. ion FAB) 1523 (M⁻), 1433, 297, 248, 205, 148, 44, 25 (100).

- 30 Anal. Calcd for C₈₃H₁₁₇N₃O₂₃·7H₂O C, 60.40; H, 7.09; N, 2.54
Found: C, 60.54; H, 7.28; N, 2.56

- 18 -

Example 8

Rapamycin-31,42-diester with 3-[[[1,1-dimethylethoxy]carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid

5

Under anhydrous conditions, 532 mg (2.18 mmol) of 2,4,6 trichlorobenzoyl chloride in 1 mL THF was added to a solution of 704 mg (2.18 mmol) of N α -Boc-L-aspartic acid- α -benzyl ester and 303 μ L (2.18 mmol) of Et₃N in 5 mL of THF at room temperature. After stirring for 20 minutes, the reaction mixture was filtered over
10 sintered glass, and the precipitate was washed with THF. The filtrate was concentrated *in vacuo* to give a thick oil. The oil was dissolved in 5 mL of benzene and 1.00 g (1.09 mmol) of rapamycin and 532 mg (4.36 mmol) of dimethylaminopyridine in 1 mL of benzene was added dropwise. The reaction was stirred for 2 hr, poured into ethyl acetate, and washed consecutively with 0.5 N HCl and brine. The solution was dried
15 over sodium sulfate, decanted, concentrated *in vacuo* to give a white foamy solid, which was purified via flash chromatography on a 60 mm x 100 mm silica column (20-40 % ethyl acetate/hexane as eluant) to give 532 mg (33 %) of the title compound which was isolated as the hydrate.

¹H NMR (CDCl₃, 400 MHz) δ 7.362 (s, 10 H, Ar), 5.193 (s, 4 H, CH₂Ph),
20 4.596 (m, 1 H, CH-CO₂), 4.586 (m, 2 H, NH), 3.336 (s, 3 H, CH₃O), 3.306 (s, 3 H, CH₃O), 3.145 (s, 3 H, CH₃O); IR (KBr) 3410 (OH), 2950 (CH), 2920 (CH), 1735 (C=O), 1710 (C=O), 1640, 1490, 1445, 1350, 1150 cm⁻¹; MS (neg. ion FAB) 1524 (M⁻), 1434, 297, 248, 232, 214, 205, 167, 148, 42 (100), 26.

Anal. Calcd for C₈₃H₁₁₇N₃O₂₃ · H₂O: C, 65.38; H, 7.73; N, 2.76
25 Found: C, 64.85; H, 7.67; N, 2.56

Example 9

30 Rapamycin-42-ester with 3-[[[1,1-dimethylethoxy]carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid

The title compound (374 mg, 23%) was prepared by the method described in the previous Example and separated from the compound described in the previous
35 Example by flash chromatography (20-40% ethyl acetate/hexane as the eluant) and isolated as the sesquihydrate.

- 19 -

¹H NMR (CDCl₃, 400 MHz) δ 7.356 (s, 5 H, Ar), 5.185 (s, 2 H, CH₂Ph), 4.635 (m, 1 H, CH-CO₂), 4.582 (m, 1 H, NH), 3.330 (s, 6 H, CH₃O), 3.135 (s, 3 H, CH₃O); IR (KBr) 3410 (OH), 2950 (CH), 2920 (CH), 1735 (C=O), 1710 (C=O), 1640, 1490, 1445, 1350, 1150 cm⁻¹; MS (neg. ion FAB) 1213 (M⁻), 1127, 590, 168, 42, 25, 17 (100).

Anal. Calcd for C₆₇H₉₈N₂O₁₈ · 1.5 H₂O: C, 63.64; H, 8.21; N, 2.22

Found: C, 63.64; H, 7.51; N, 2.13

Example 10

Rapamycin-42-ester with 5-(1,1-dimethoxy)-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid

Under anhydrous conditions, an ice cold solution of rapamycin (4 g, 4.37 mmole) and L-glutamic acid N^α-Boc-α-tert-butylester (4.9 g, 16.1 mmole) in 40 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.8 g, 8.7 mmole) followed by 4-dimethylamino pyridine (1 g, 8.7 mmole). After stirring overnight at ambient temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were concentrated *in vacuo* to give 9 g of an amorphous amber solid. The crude product was purified by flash chromatography (on silica Merck 60, gradient elution with hexane-ethylacetate from 2:1 to 3:2, v/v) to provide 1.35 g (25.7%) of the title compound along with the 31,42-diester of Example 11. HPLC analysis showed that the monoester is a 7.5 : 1 mixture of two conformers.

¹H NMR (CDCl₃, 400 MHz): δ 1.43 (s, 9H, COOBu^t) and 1.46 (s, 9H, COOBu^t), 1.65 (s, 3H, CH₃C=C), 1.75 (s, 3H, CH₃C=C), 3.14 (s, 3H, CH₃O), 3.34 (s, 3H, CH₃O), 3.38 (s, 3H, CH₃O), 4.18 (d, 1H, CH-OH), 4.65 (m, 1H, 42-CHO), 4.80 (s, 1H, OH);

High Res. MS (neg. ion FAB): Calc. for C₆₅H₁₀₂N₂O₁₈: 1198.7126, measured mass 1198.7135.

Anal. Calcd for C₆₅H₁₀₂N₂O₁₈: C, 65.09; H, 8.57; N, 2.34

Found C, 65.04; H, 8.33; N, 2.64

- 20 -

Example 11

Rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-4-[[[(1,1-dimethylethoxy)-carbonyl]-amino]-5-oxopentanoic acid

5

The title compound was prepared (0.83 g, 12.8%) along with the 42-monoester as described in Example 10. HPLC analysis showed that the diester is a 7.7:1 mixture of two conformers.

10

¹H NMR (CDCl₃, 400 MHz): δ 1.43 (s, 18H, COOBu^t), 1.46 (s, 18H, COOBu^t), 1.659 (s, 3H, CH₃C=C), 1.759 (s, 3H, CH₃C=C), 3.14 (s, 3H, CH₃O), 3.34 (s, 3H, CH₃O), 3.38 (s, 3H, CH₃O), 4.66 (m, 1H, 42-CHO), 4.72 (s, 1H, OH); High Res. MS (neg. ion FAB): Calcd for C₇₉H₁₂₅N₃O₂₃: 1483.8704, measured mass 1483.8636.

15

Anal. Calcd for C₇₉H₁₂₅N₃O₂₃: C, 63.90; H, 8.49; N, 2.83

Found: C, 63.68; H, 8.60; N, 3.20

20

Example 12

Rapamycin-42-ester with N^α, N^ε-bis[(1,1-dimethylethoxy)carbonyl]-L-lysine

25

Under anhydrous conditions, a solution of rapamycin (3 g, 3.28 mmole) and N^α, N^ε-bis-Boc-L-lysine (4.5 g, 13 mmole) in 40 mL of anhydrous dichloromethane was treated with dicyclohexylcarbodiimide (1.35 g, 6.56 mmole) followed by 4-dimethylaminopyridine (0.8 g, 6.56 mmole). After stirring overnight at ambient temperature, the precipitated solid was collected and washed with dichloromethane. The combined filtrates were concentrated *in vacuo* to give an amorphous amber solid. Flash chromatography of the crude product (on silica Merck 60, elution with hexane-ethylacetate 1:1 v/v) gave partially purified title compound. Pure product (0.8 g, 19.6%) was obtained by preparative HPLC (Waters Prep 500, silica gel, hexane-ethylacetate 3:2 v/v, flow rate 250 mL/min). HPLC analysis showed that the monoester is a 9:1 mixture of two conformers.

35

- 21 -

^1H NMR (CDCl_3 , 400 MHz): δ 1.438 (m, 9H, COO^tBu), 1.455 (s, 9H, COO^tBu), 1.652 (s, 3H, $\text{CH}_3\text{C}=\text{C}$), 1.752 (s, 3H, $\text{CH}_3\text{C}=\text{C}$), 3.14 (s, 3H, CH_3O), 3.33 (s, 3H, CH_3O), 3.37 (s, 3H, CH_3O), 4.18 (d, 1H, CHOH), 4.72 (m, 1H, 42-CHO), 4.79 (s, 1H, OH); High Res. MS (neg. ion FAB): Calcd for $\text{C}_{67}\text{H}_{107}\text{N}_3\text{O}_{18}$:

5 1241.7549, measured mass 1241.7604.

Anal. Calcd for $\text{C}_{67}\text{H}_{107}\text{N}_3\text{O}_{18}$: C, 64.76; H, 8.68; N, 3.38

Found: C, 64.58; H, 9.01; N, 3.10

10 Example 13

Rapamycin-31,42-diester with $\text{N}^\alpha, \text{N}^\epsilon$ -bis[(1,1-dimethylethoxy)carbonyl]-L-lysine

Under a nitrogen atmosphere, a solution of $\text{N}^\alpha, \text{N}^\epsilon$ bis-Boc-L-lysine (1.038 g, 3 mmole) and triethylamine (0.42 mL, 3 mmole) in 10 mL of anhydrous THF was treated in one portion with 2,4,6-trichlorobenzoyl chloride (0.73 g, 3 mmole). After stirring for 20 minutes at ambient temperature, the precipitated solid was collected and the filtrate was concentrated *in vacuo*. The resulting mixed anhydride was dissolved in 5 mL of benzene and added to a stirred solution of rapamycin (1 g, 1.09 mmole) containing 4-dimethylamino pyridine (0.59 g, 4.8 mmole) in 10 mL of benzene. After stirring at ambient temperature overnight, the precipitated solid was collected and the filtrate was evaporated to dryness (yellow foam). The crude product was purified by flash chromatography (on silica Merck 60, elution with hexane-ethylacetate 1:1) to provide title compound (1.15 g, 67%). HPLC analysis shows that the diester is a 9:1 mixture of two conformers.

^1H NMR (CDCl_3 , 400 MHz): δ 1.426 (m, 9H, COO^tBu), 1.438 (s, 9H, COO^tBu), 1.443 (s, 9H, COO^tBu), 1.446 (s, 9H, COO^tBu), 3.141 (s, 3H, CH_3O), 3.36 (s, 3H, CH_3O), 3.378 (s, 3H, CH_3O), 4.68-4.76 (m, 2H, OH and 42-CHO); High res. MS (neg. ion FAB): Calcd. for $\text{C}_{83}\text{H}_{135}\text{N}_5\text{O}_{23}$ 1569.9526, measured mass 1569.9537.

30 Anal. Calcd. for $\text{C}_{83}\text{H}_{135}\text{N}_5\text{O}_{23}$: C, 63.46; H, 8.66; N, 4.46

Found: C, 63.06; H, 8.34; N, 4.09

Example 14.

Rapamycin-14,31,42-tris(monobenzy succinate)

5 To a solution of 5.0 g (5.47 mmol) of rapamycin, 3.41 g (16.41 mmol) of monobenzy succinate, and 3.15 g (16.41 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in 20 mL of dry dichloromethane was added 200 mg of 4-dimethylaminopyridine. The solution was stirred at room temperature for 3 days. The reaction mixture was poured into 2 N HCl and extracted three times with ethyl acetate. The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, decanted, and concentrated in vacuo to give a light yellow foam. Flash chromatography on a 60 mm x 150 mm silica gel column eluting with 20 % ethyl acetate/hexane to 75 % ethyl acetate/hexane gave three fractions. Fraction #1, upon concentration, gave 330 mg (4.1 %) of pure rapamycin-14,31,42-tris-

10 (monobenzy succinate).

¹H NMR (CDCl₃, 400 MHz) δ 7.353 (bs, 15 H, *arom*), 5.168 (d, J = 2.0 Hz, 1 H, CH-O₂C), 5.148 (m, 6 H, CH₂Ph), 4.672 (m, 1 H, CO₂CH-CHOMe), 3.355 (s, 3 H, CH₃O-), 3.337 (s, 3 H, CH₃O-), 3.327 (s, 3 H, CH₃O-), 2.697 (m, 12 H, O₂CCH₂CH₂CO₂CH₂Ph), 1.745 (s, 3 H, CH₃C=C), 1.655 (s, 3 H, CH₃C=C);

20 IR (KBr) 3450 (OH), 2950 (CH), 1745 (C=O), 1650, 1460, 1385, 1360, 1160, 1105, 995 cm⁻¹.

Analysis Calcd for C ₈₄ H ₁₀₉ NO ₂₁ · 3 H ₂ O	C 66.27;	H 7.56;	N 0.92
Found	C 65.96;	H 7.24;	N 1.00

25 The following representative compounds can be prepared from rapamycin and the appropriate half acid-ester by employing the method used to prepare the title compound in Example 14.

30 Rapamycin-14,31,42-tris (monomethylsuccinate)
 Rapamycin-14,31,42-tris (monophenyl-3',3'-dimethylglutarate)
 Rapamycin-14,31,42-tris (mono t-butyl-3'-methylglutarate)
 Rapamycin-14,31,42-tris (monobenzyliodiglycolate)
 Rapamycin-14,31,42-tris (monohexyldiglycolate)
 Rapamycin-14,31,42-tris (monopropylphthalate)
 35 Rapamycin-14,31,42-tris (monoethyl-2',6'-pyridinedicarboxylate)

- 23 -

Example 15.Rapamycin-31,42-bis(monobenzy succinate)

5 Fraction # 2, obtained from the procedure employed in Example 14, gave 1.25 g (17.7 %) of pure rapamycin-31,42-bis(monobenzy succinate) upon concentration.

¹H NMR (CDCl₃, 400 MHz) δ 7.351 (bs, 10 H, *arom*), 5.168 (d, J = 2.0 Hz, 1 H, CH-O₂C), 5.125 (m, 4 H, CH₂Ph), 4.680 (m, 1 H, CO₂CH-CHOMe), 3.356 (s, 3 H, CH₃O-), 3.329 (s, 3 H, CH₃O-), 3.146 (s, 3 H, CH₃O-), 2.639 (m, 8 H, O₂CCH₂CH₂CO₂CH₂Ph), 1.748 (s, 3 H, CH₃C=C), 1.654 (s, 3 H, CH₃C=C); IR (KBr) 3450 (OH), 2940 (CH), 1740 (C=O), 1650, 1455, 1380, 1355, 1160, 1105, 995 cm⁻¹; MS (neg. ion FAB) 1294 (M⁻), 1202, 1103, 1012, 590, 511, 475, 297, 207, 167, 148, 99 (100); High Res. MS (neg. ion FAB) Calcd for C₇₃H₉₉NO₁₉ 1293.68108, found 1293.6811.

Analysis Calcd for C ₇₃ H ₉₉ NO ₁₉ · H ₂ O	C 66.82;	H 7.70;	N 1.07
Found	C 67.17;	H 7.67;	N 1.23

20 The following representative compounds can be prepared from rapamycin and the appropriate half acid-ester by employing the method used to prepare the title compound in Example 15.

25 Rapamycin-31,42-bis (monomethylsuccinate)
 Rapamycin-31,42-bis (monophenyl-3',3'-dimethylglutarate)
 Rapamycin-31,42-bis (mono t-butyl-3'-methylglutarate)
 Rapamycin-31,42-bis (monobenzyldiglycolate)
 Rapamycin-31,42-bis (monohexyldiglycolate)
 30 Rapamycin-31,42-bis (monopropylphthalate)
 Rapamycin-31,42-bis (monoethyl-2',6'-pyridinedicarboxylate)

Example 16.35 Rapamycin-42-(monobenzy succinate)

Fraction # 3, obtained from the procedure employed in Example 14, gave 930 mg (15.4 %) of pure rapamycin-42-monobenzy succinate upon concentration.

- 24 -

¹H NMR (CDCl₃, 400 MHz) δ 7.355 (bs, 5 H, *arom*), 5.141 (m, 2 H, CH₂Ph), 4.680 (m, 1 H, CO₂CH-CHOMe), 3.364 (s, 3 H, CH₃O-), 3.333 (s, 3 H, CH₃O-), 3.141 (s, 3 H, CH₃O-), 2.698 (m, 4 H, O₂CCH₂CH₂CO₂CH₂Ph), 1.751 (s, 3 H, CH₃C=C), 1.655 (s, 3 H, CH₃C=C); IR (KBr) 3450 (OH), 2940 (CH), 1740 (C=O), 1645, 1455, 1380, 1165, 1105, 990 cm⁻¹; MS (neg. ion FAB) 1103 (M⁻), 1045, 1012, 624, 590, 167, 99 (100); High Res. MS (neg. ion FAB) Calcd for C₆₂H₈₉NO₁₆ 1103.6181, found 1103.6048.

Analysis Calcd for C ₆₂ H ₈₉ NO ₁₆ · H ₂ O	C 66.36;	H 8.02;	N 1.24
Found	C 66.02;	H 7.69;	N 1.26

The following representative compounds can be prepared from rapamycin and the appropriate half acid-ester by employing the method used to prepare the title compound in Example 16.

- 15 Rapamycin-42-(monomethylsuccinate)
- Rapamycin-42-monophenyl-3',3'-dimethylglutarate)
- Rapamycin-42-(mono t-butyl-3'-methylglutarate)
- Rapamycin-42-(monobenzylthiodiglycolate)
- Rapamycin-42-(monohexyldiglycolate)
- 20 Rapamycin-42-(monopropylphthalate)
- Rapamycin-42-(monoethyl-2',6'-pyridinedicarboxylate)

Example 17.

Rapamycin-31,42-bishemiglutarate

To a solution of 2.0 g (2.2 mmol) of rapamycin in 10 mL of dry dichloromethane was added 1.24 g (10.9 mmol) of glutaric anhydride followed by 881 μ L (861 mg, 10.9 mmol) of pyridine. To this was added 200 mg of 4-dimethylaminopyridine and the reaction mixture was allowed to reflux for 8 h. The solution was cooled to room temperature, poured into 2 N HCl, and extracted three times with dichloromethane. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, decanted, and concentrated *in vacuo* to give a yellow foam. The crude product was purified via reverse phase HPLC on a C₁₈ column eluting starting with 60 % acetonitrile/water. Collected, after, concentration, 586 mg (24 %) of rapamycin-31,42-bishemiglutarate.

- 25 -

- ¹H NMR (CDCl₃, 400 MHz) δ 5.398 (m, 1 H, -CO₂CHCHOMe), 4.683 (m, 1 H, -CO₂CHCHOMe), 3.364 (s, 3 H, CH₃O-), 3.362 (s, 3 H, CH₃O-), 3.106 (s, 3 H, CH₃O-), 2.407 (m, 8 H, -O₂CCH₂CH₂CH₂CO₂H), 1.960 (m, 4 H, -O₂CCH₂CH₂CH₂CO₂H), 1.770 (s, 3 H, CH₃C=C), 1.653 (s, 3 H, CH₃C=C);
- 5 ¹³C NMR (CDCl₃, MHz) 211.45 (C=O), 206.84 (C=O), 200.44 (C=O), 177.83 (C=O), 177.04 (C=O), 172.43 (C=O), 171.20 (C=O), 165.27 (C=O), 159.08 (C=O); IR (KBr) 3430 (OH), 2940 (CH), 2880 (CH), 1745 (C=O), 1685, 1625, 1580, 1450, 1385, 1330, 1200, 1140, 1100, 990 cm⁻¹; MS (neg. ion FAB) 1140 (M-H), 1122, 1026, 990, 946, 913, 590, 475, 435, 321, 167, 148, 131 (100), 113; High Res.
- 10 MS (neg. ion FAB) Calcd for C₆₁H₉₉O₁₉N (M-H) 1140.6107, Found 1140.6106.
- | | | | |
|---|----------|---------|--------|
| Analysis Calcd for C ₆₁ H ₉₁ O ₁₉ N · H ₂ O | C 63.15; | H 8.02; | N 1.20 |
| Found | C 63.35; | H 7.88; | N 1.40 |

- 15 The following representative compounds can be prepared from rapamycin and the appropriate anhydride by employing the method used to prepare the title compound in Example 17.

- 20 Rapamycin-31,42-bishemi-3'-methylglutarate
 Rapamycin-31,42-bishemi-3',3'-dimethylglutarate
 Rapamycin-31,42-bishemi-3'-oxoglutarate
 Rapamycin-31,42-bishemi-3'-thioglutarate
 Rapamycin-31,42-bishemi-phthalate
 Rapamycin-31,42-bishemi-2',3'-pyridine dicarboxylate.

25

Example 18.

Rapamycin-31,42-hemiglutarate bis-sodium salt

- 30 Purified bis-31,42-hemiglutarate of rapamycin (740 mg, 649 μmol), prepared as described in Example 17, was dissolved in 5 mL of 95 % ethanol and 107 mg (1.27 mmol) of sodium bicarbonate was added. Water (1 mL) was added to completely dissolve the salt. Once dissolved, the light yellow solution was concentrated in vacuo to give a foamy yellow solid. The foam was dried in a drying
- 35 pistol for 24 h, refluxing over acetone at reduced pressure to give 520 mg of the bis-sodium salt.

- 26 -

¹H NMR (d₆-DMSO, 400 MHz) δ 5.235 (m, 1 H, -CHO₂C), 4.498 (m, 1 H, MeOCHCHO₂C-), 3.287 (s, 6 H, 2 CH₃O-), 3.235 (s, 3 H, CH₃O-), 2.245 (m, 8 H, O₂CCH₂CH₂CH₂CO₂-), 1.712 (s, 3 H, CH₃C=C), 1.593 (s, 3 H, CH₃C=C); IR (KBr) 3420 (OH), 2920 (CH), 1725 (C=O), 1675, 1620, 1560, 1450, 1400, 1375, 1230, 1195, 1130, 1090, 980 cm⁻¹; MS (neg. ion FAB) 1112 (M-1, free acid), 994, 589, 475, 297, 167, 148, 117, 99 (100); High Res. MS (neg. ion FAB) Calcd for C₆₁H₈₉O₁₉NNa (M-Na) 1162.5926, Found 1162.5899.

Analysis Calcd for C₆₁H₈₉O₁₉NNa₂ · H₂O C 60.85; H 7.56; N 1.16
Found C 60.67; H 7.36; N 1.58

Example 19.

Rapamycin-31,42-bis(hemiglutarate bistromethamine salt)

Purified bis-31,42 hemiglutarate of rapamycin (950 mg, 833 μmol), prepared as described in Example 17, was dissolved in 5 mL of 95 % ethanol and 197 mg (1.63 mmol) of tris(hydroxymethyl)methylamine was added. Water (1 mL) was added to completely dissolve the amine. Once dissolved, the yellow solution was concentrated in vacuo to give a foamy yellow solid. The very hygroscopic foam was dried in a drying pistol for 24 h, refluxing over acetone at reduced pressure to give 900 mg (78 %) of the bistromethamine salt.

¹H NMR (d₆-DMSO, 400 MHz) δ 5.253 (m, 1 H, -CHO₂C), 4.523 (m, 1 H, MeOCHCHO₂C-), 3.347 (s, 6 H, 2 CH₃O-), 3.276 (s, 3 H, CH₃O-), 2.289 (m, 8 H, O₂CCH₂CH₂CH₂CO₂-), 1.681 (s, 3 H, CH₃C=C), 1.595 (s, 3 H, CH₃C=C); IR (KBr) 3400 (OH), 2920 (CH), 1730 (C=O), 1620, 1555, 1450, 1400, 1370, 1185, 1060, 980 cm⁻¹; MS (neg. ion FAB) 1140 (M-H, free acid), 1028, 167, 148, 131 (100), 113; High Res. MS (neg. ion FAB) Calcd for C₆₁H₉₀O₁₉N (M-H, free acid) 1140.6107, Found 1140.6069.

Analysis Calcd for C₆₉H₁₀₃O₂₅N₃ · 2 H₂O C 58.77; H 7.58; N 2.98
Found C 58.47; H 7.94; N 3.58

- 27 -

Example 20.

Rapamycin-42-hemi-3'-oxoglutarate

5 To a solution of 3.0 g (3.3 mmol) of rapamycin in 20 mL of dry dichloromethane was added 1.90 g (16.4 mmol) of diglycolic anhydride followed by 1.32 mL (1.29 g, 16.4 mmol) of pyridine. To this was added 200 mg of 4-dimethylaminopyridine and the reaction mixture was allowed to stir at room temperature for 2 days. The solution was cooled to room temperature, poured into 2 N HCl, and extracted three times with dichloromethane. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, decanted, and concentrated in vacuo to give a yellow foam. The crude product was purified via reverse phase HPLC on a C₁₈ column eluting starting with 60 % acetonitrile/water. After concentration, 870 mg (26 %) of rapamycin-42-hemi-3'-oxoglutarate and 15 500 mg (13 %) of rapamycin-31,42-bishemi-3'-oxoglutarate were isolated.

¹H NMR (CDCl₃, 400 MHz) δ 4.768 (m, 1 H, CO₂CH-CHOMe), 4.250 (m, 4 H, O₂CCH₂OCH₂CO₂), 3.356 (s, 3 H, CH₃O-), 3.331 (s, 3 H, CH₃O-), 3.139 (s, 3 H, CH₃O-), 1.759 (s, 3 H, CH₃C=C), 1.653 (s, 3 H, CH₃C=C); IR (KBr) 3420 (OH), 2920 (CH), 2875 (CH), 1740 (C=O), 1720 (C=O), 1640, 1625, 20 1445, 1370, 1320, 1200, 1135, 1095, 980 cm⁻¹; MS (neg. ion FAB) 1028 (M - H), 327, 167 (100), 148, 133, 115; High Res. MS (neg. ion FAB) Calcd for C₅₅H₈₂O₁₇N (M - H) 1028.5597, Found 1028.5599.

Analysis Calcd for C₅₅H₈₃O₁₇N · 3 H₂O C 60.97; H 8.22; N 1.29
Found C 61.33; H 7.74; N 1.69

25

The following representative compounds can be prepared from rapamycin and the appropriate half acid-ester by employing the method used to prepare the title compound in Example 20.

30 Rapamycin-42-hemi-3'-methylglutarate
Rapamycin-42-hemi-3',3'-dimethylglutarate
Rapamycin-42-hemi-3'-thioglutarate
Rapamycin-42-hemi-phthalate
Rapamycin-42-hemi-2',3'-pyridine dicarboxylate

35

- 28 -

Example 21.

Rapamycin-31,42-bishemi-3'-oxoglutarate

5 To a solution of 5.0 g (5.47 mmol) of rapamycin in 20 mL of dry dichloromethane was added 3.17 g (27.3 mmol) of diglycolic anhydride followed by 2.17 mL (2.12 g, 27.3 mmol) of pyridine. To this was added 400 mg of 4-dimethylaminopyridine and the reaction mixture was allowed to stir at reflux for 24 h. The solution was cooled to room temperature, poured into 2 N HCl, and extracted three
 10 times with dichloromethane. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, decanted, and concentrated *in vacuo* to give a yellow foam. The crude product was purified via reverse phase HPLC on a C₁₈ column eluting starting with 60 % acetonitrile/water. After concentration, 1.75 g (28 %) of rapamycin-31,42-bishemi-3'-oxoglutarate was isolated.

15 ¹H NMR (CDCl₃, 400 MHz) δ 4.785 (m, 1 H, CO₂CHCHOMe), 4.260 (m, 8 H, O₂CCH₂OCH₂CO₂), 3.360 (s, 3 H, CH₃O-), 3.343 (s, 3 H, CH₃O-), 3.143 (s, 3 H, CH₃O-), 1.775 (s, 3 H, CH₃C=C), 1.656 (s, 3 H, CH₃C=C);
¹³C NMR (CDCl₃, MHz) 211.12 (C=O), 207.73 (C=O), 193.11 (C=O), 171.90 (C=O), 171.59 (C=O), 170.15 (C=O), 169.35 (C=O), 168.83 (C=O), 166.63 (C=O);
 20 IR (KBr) 3420 (OH), 2920 (CH), 2850 (CH), 1740 (C=O), 1645, 1625, 1440, 1370, 1190, 11300, 980 cm⁻¹; MS (neg. ion FAB) 1140 (M-H), 1122, 1026, 990, 946, 913, 590, 475, 435, 321, 167, 148, 131 (100), 113; High Res. MS (neg. ion FAB) Calcd for C₅₉H₈₆O₂₁N (M - H) 1144.5701, Found 1144.5702.

25	Analysis Calcd for C ₅₉ H ₈₇ O ₂₁ N	C 61.82;	H 7.65;	N 1.22
	Found	C 61.59;	H 7.36;	N 1.84

Example 22.

30 Rapamycin-31,42-bishemi-3'-oxoglutarate disodium salt

Purified bis-31,42 hemi-3'-oxoglutarate of rapamycin (720 mg, 629 μmol), prepared by the procedure employed in Example 21, was dissolved in 10 mL of 95 % ethanol and 106 mg (1.26 mmol) of sodium bicarbonate was added. Water (1 mL) was
 35 added to completely dissolve the salt. Once dissolved, the light yellow solution was concentrated *in vacuo* to give a foamy yellow solid. The foam was dried in a drying

- 29 -

pistol for 48 h, refluxing over dichloromethane at reduced pressure to give 435 mg (58 %) of the disodium salt.

¹H NMR (d₆-DMSO, 400 MHz) δ 4.975 (m, 1 H, -CHO₂C), 4.593 (m, 1 H, MeOCHCHO₂C-), 4.135 (s, 2 H, -O₂CCH₂OCH₂CO₂R), 3.617 (s, 2 H, -O₂CCH₂OCH₂CO₂R), 3.299 (s, 6 H, 2 CH₃O-), 3.232 (s, 3 H, CH₃O-), 1.614 (s, 3 H, CH₃C=C), 1.553 (s, 3 H, CH₃C=C); IR (KBr) 3420 (OH), 2920 (CH), 1735 (C=O), 1615, 1445, 1395, 1380, 1320, 1220, 1130, 1090, 980 cm⁻¹; MS (neg. ion FAB) 1188 (M-1), 1166 (M-Na), 1144, 1051, 1028, 590, 459, 167, 155 (100), 148, 133, 115.

Analysis Calcd for C₅₉H₈₅O₂₁NNa₂ · 2H₂O C 57.79; H 7.26; N 1.14
Found C 57.94; H 7.11; N 1.26

Example 23.

Rapamycin-31,42-hemi-3'-oxoglutarate bistromethamine salt

Purified bis-31,42 hemi-3'-oxoglutarate of rapamycin (1.01 g, 882 μmol), prepared by the procedure employed in Example 21, was dissolved in 10 mL of 95 % ethanol and 213 mg (1.76 mmol) of tris(hydroxymethyl)- methylamine was added. Water (1 mL) was added to completely dissolve the amine. Once dissolved, the yellow solution was concentrated in vacuo to give a foamy yellow solid. The very hygroscopic foam was dried in a drying pistol for 48 h, refluxing over dichloromethane at reduced pressure to give 805 mg (66 %) of the bistromethamine salt.

¹H NMR (d₆-DMSO, 400 MHz) δ 4.955 (m, 1 H, -CHO₂C), 4.600 (m, 1 H, MeOCHCHO₂C-), 4.149 (s, 2 H, -O₂CCH₂OCH₂CO₂R), 3.770 (s, 2 H, -O₂CCH₂OCH₂CO₂R), 3.407 (s, 6 H, 2 CH₃O-), 3.257 (s, 3 H, CH₃O-), 1.806 (s, 3 H, CH₃C=C), 1.614 (s, 3 H, CH₃C=C); IR (KBr) 3400 (OH), 2920 (CH), 1730 (C=O), 1620, 1550, 1450, 1395, 1370, 1200, 1060, 985 cm⁻¹; MS (neg. ion FAB) 1144 (M-H, free acid), 1028, 167, 148, 133 (100), 115.

Analysis Calcd for C₆₇H₁₀₉O₂₇N₃ · H₂O C 57.22; H 7.90; N 2.98
Found C 57.26; H 7.90; N 3.15

- 30 -

Example 24.

Rapamycin-31,42-bishemisuccinate.

5 To a solution of 2.0 g (2.2 mmol) of rapamycin in 10 mL of dry dichloromethane was added 1.19 g (10.9 mmol) of succinic anhydride followed by 881 μ L (861 mg, 10.9 mmol) of pyridine. To this was added 200 mg of 4-dimethylamino-pyridine and the reaction mixture refluxed for 24 h. The solution was cooled to room temperature, poured into 2 N HCl, and extracted three times with dichloromethane.
10 The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, decanted, and concentrated in vacuo to give a yellow foam. The crude product was purified via reverse phase HPLC on a C₁₈ column gradient eluting starting with 20 % acetonitrile/water to 60 % acetonitrile/water. Collected, after, concentration, 770 mg (31 %) of rapamycin-31,42-bishemisuccinate.

15 The purified bis-31,42 hemisuccinate of rapamycin (770 mg, 686 μ mol) was dissolved in 10 mL of 95 % ethanol and 166 mg (1.37 mmol) of tris(hydroxymethyl)-methylamine was added. Water (1 mL) was added to completely dissolve the amine. Once dissolved, the yellow solution was concentrated in vacuo to give a foamy yellow
20 solid. The very hygroscopic foam was dried in a drying pistol for 24 h, refluxing over acetone at reduced pressure to give 890 mg (95 %) of the bistromethamine salt. The bistromethane salt was evaluated in the standard pharmacological test procedures.

¹H NMR (d_6 -DMSO, 400 MHz) 5.231 (m, 1 H, -CHO₂C), 4.554 (m, 1 H, MeOCHCHO₂C-), 3.426 (s, 6 H, 2 CH₃O-), 3.249 (s, 3 H, CH₃O-), 2.431 (m, 8 H, O₂CCH₂CH₂CO₂-), 1.700 (s, 3 H, CH₃C=C), 1.554 (s, 3 H, CH₃C=C); ¹³C NMR (d_6 -DMSO,) 211.28 (C=O), 205.23 (C=O), 199.59 (C=O), 174.86 (C=O), 173.62 (C=O), 171.72 (C=O), 171.50 (C=O), 166.56 (C=O), 166.53 (C=O); IR (KBr) 3420 (OH), 2940 (CH), 1735 (C=O), 1630, 1580, 1460, 1400, 1380, 1170, 1070,
30 990 cm⁻¹; MS (neg. ion FAB) 1112 (M-1, free acid), 994, 589, 475, 297, 167, 148, 117, 99 (100).

Analysis Calcd for C ₆₇ H ₁₀₉ O ₂₅ N ₃ · 2 H ₂ O	C 57.80;	H 8.12;	N 3.01
Found	C 57.91;	H 8.21;	N 2.37


- 31 -

CLAIMS


What is claimed is:

1. A compound of the structure

5



wherein R^1 , R^2 , and R^3 are each, independently, hydrogen, or R^4 ;



R^5 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms,

- 15 $-(\text{CH}_2)_q\text{CO}_2\text{R}^8$, $-(\text{CH}_2)_r\text{NR}^9\text{CO}_2\text{R}^{10}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted
- 20 with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

- 32 -

R^6 and R^9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;

5 R^7 , R^8 , and R^{10} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

10 R^{11} and R^{12} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

X is $\begin{array}{c} R^{13} \\ | \\ -C- \\ | \\ R^{14} \end{array}$, O, or S;

15

R^{13} and R^{14} are each, independently, hydrogen or alkyl of 1-6 carbon atoms;

Y is CH or N;

m is 0 - 4;

n is 0 - 4;

20 p is 1 - 2;

q is 0 - 4;

r is 0 - 4;

t is 0 - 4;


u is 0 - 4;

wherein R^5 , R^6 , m , and n are independent in each of the $\begin{array}{c} O \\ || \\ [C(CH_2)_mCH(CH_2)_nN] \\ | \quad | \\ R^5 \quad R^6 \end{array}$


25 subunits when $p = 2$;

or a pharmaceutically acceptable salt thereof, with the proviso that R^1 , R^2 , and R^3 are not all hydrogen, further provided that R^1 , R^2 , and R^3 are not all


- 33 -




both 0 when X is O or S.




5 m = 0, n = 0, and p = 1 or a pharmaceutically acceptable salt thereof.




m = 0, n = 0, and p = 2 or a pharmaceutically acceptable salt thereof.



10 n = 0, and R⁵ is $-(\text{CH}_2)_q\text{CO}_2\text{R}^8$ or a pharmaceutically acceptable salt thereof.



15 m = 0, n = 0, and R⁵ is $-(\text{CH}_2)_r\text{NR}^9\text{CO}_2\text{R}^{10}$ or a pharmaceutically acceptable salt thereof.



m = 0, n = 0, and R⁵ is hydrogen or a pharmaceutically acceptable salt thereof.

- 34 -


7. A compound of claim 1 where R⁴ is $\text{--}\overset{\text{O}}{\underset{\parallel}{\text{C}}}-(\text{CH}_2)_i\text{X}(\text{CH}_2)_u\text{CO}_2\text{R}^{11}$ or a pharmaceutically acceptable salt thereof.
- 5 8. A compound of claim 1 which is rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-glycylglycine or a pharmaceutically acceptable salt thereof.
9. A compound of claim 1 which is rapamycin-31,42-diester with N-[(1,1-dimethyl-ethoxy)carbonyl]-glycylglycine or a pharmaceutically acceptable salt thereof.
- 10 10. A compound of claim 1 which is rapamycin-31,42-diester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine or a pharmaceutically acceptable salt thereof.
11. A compound of claim 1 which is rapamycin-42-ester with N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine or a pharmaceutically acceptable salt thereof.
- 15 12. A compound of claim 1 which is rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof.
- 20 13. A compound of claim 1 which is rapamycin-42-ester with 5-(1,1-dimethylethoxy)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof.
- 25 14. A compound of claim 1 which is rapamycin-31,42-diester with 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid or a pharmaceutically acceptable salt thereof.
- 30 15. A compound of claim 1 which is rapamycin-31,42-diester with 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid or a pharmaceutically acceptable salt thereof.
- 35 16. A compound of claim 1 which is rapamycin-42-ester with 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxo-4-(phenylmethoxy) butanoic acid or a pharmaceutically acceptable salt thereof.

- 35 -

17. A compound of claim 1 which is rapamycin-42-ester with 5-(1,1-dimethylethoxy)-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof.
- 5 18. A compound of claim 1 which is rapamycin-31,42-diester with 5-(1,1-dimethylethoxy)-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxopentanoic acid or a pharmaceutically acceptable salt thereof.
- 10 19. A compound of claim 1 which is rapamycin-42-ester with N α , N ϵ -bis[(1,1-dimethylethoxy)carbonyl]-L-lysine or a pharmaceutically acceptable salt thereof.
20. A compound of claim 1 which is rapamycin-31,42-diester with N α , N ϵ -bis[(1,1-dimethylethoxy)carbonyl]-L-lysine or a pharmaceutically acceptable salt thereof.
- 15 21. A compound of claim 1 which is rapamycin-14,31,42-tris(monobenzy succinate) or a pharmaceutically acceptable salt thereof.
22. A compound of claim 1 which is rapamycin-31,42-bis(monobenzy succinate) or a pharmaceutically acceptable salt thereof.
- 20 23. A compound of claim 1 which is rapamycin-42-(monobenzy succinate) or a pharmaceutically acceptable salt thereof.
- 25 24. A compound of claim 1 which is rapamycin-31,42-bishemiglu tarate or a pharmaceutically acceptable salt thereof.
25. A compound of claim 1 which is rapamycin-31,42-hemiglu tarate bis sodium salt.
- 30 26. A compound of claim 1 which is rapamycin-31,42-bishemiglu tarate bistromethamine salt.
27. A compound of claim 1 which is rapamycin-42-hemi-3'-oxoglu tarate or a pharmaceutically acceptable salt thereof.
- 35

- 36 -


28. A compound of claim 1 which is rapamycin-31,42-bishemi-3'-oxoglutarate or a pharmaceutically acceptable salt thereof.
29. A compound of claim 1 which is rapamycin-31,42-bishemi-3'-oxoglutarate
5 disodium salt.
30. A compound of claim 1 which is rapamycin-31,42-bishemi-3'-oxoglutarate bistromethamine salt.
- 10 31. A compound of claim 1 which is rapamycin-31,42-bishemisuccinate or a pharmaceutically acceptable salt thereof.
32. A compound of claim 1 which is rapamycin-31,42-bishemisuccinate
15 bistromethane salt.
33. A method of treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation in a mammal by administering an immunosuppressive amount of a compound having the structure



20

wherein R¹, R², and R³ are each, independently, hydrogen, or R⁴;

- 37 -



R⁵ is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms,

5 $-(CH_2)_qCO_2R^8$, $-(CH_2)_rNR^9CO_2R^{10}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted
10 with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

R⁶ and R⁹ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;

15 R⁷, R⁸, and R¹⁰ are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

20 R¹¹ and R¹² are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

25

X is $\begin{array}{c} \text{R}^{13} \\ | \\ -\text{C}- \\ | \\ \text{R}^{14} \end{array}$, O, or S;

R¹³ and R¹⁴ are each, independently, hydrogen or alkyl of 1-6 carbon atoms;

Y is CH or N;

30 m is 0 - 4;

- 38 -

n is 0 - 4;

p is 1 - 2;

q is 0 - 4;

r is 0 - 4;

5 t is 0 - 4;

u is 0 - 4;

wherein R^5 , R^6 , m, and n are independent in each of the $[C(CH_2)_mCH(CH_2)_nN]$

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{---} [C(CH_2)_mCH(CH_2)_nN]_p CO_2R^7 \end{array}$$

$\begin{array}{cc} | & | \\ R^5 & R^6 \end{array}$

subunits when p = 2;

or a pharmaceutically acceptable salt thereof, with the proviso that R^1 , R^2 , and R^3 are not all hydrogen, further provided that R^1 , R^2 , and R^3 are not all


10

$\begin{array}{c} \text{O} \\ \parallel \\ \text{---} [C(CH_2)_mCH(CH_2)_nN]_p CO_2R^7 \end{array}$, and still further provided that t and u are not

$\begin{array}{cc} | & | \\ R^5 & R^6 \end{array}$



both 0 when X is O or S.

34. A method of treating fungal infections which comprises administering an
15 antifungal amount of a compound having the structure




wherein R^1 , R^2 , and R^3 are each, independently, hydrogen, or R^4 ;

- 39 -



- 5 R^5 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, $-(\text{CH}_2)_q\text{CO}_2\text{R}^8$, $-(\text{CH}_2)_r\text{NR}^9\text{CO}_2\text{R}^{10}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;
- 10 R^6 and R^9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;
- 15 R^7 , R^8 , and R^{10} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;
- 20 R^{11} and R^{12} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;
- 25



- R^{13} and R^{14} are each, independently, hydrogen or alkyl of 1-6 carbon atoms;
- 30 Y is CH or N;

- 40 -

- m is 0 - 4;
 n is 0 - 4;
 p is 1 - 2;
 q is 0 - 4;
 5 r is 0 - 4;
 t is 0 - 4;
 u is 0 - 4;

wherein R^5 , R^6 , m, and n are independent in each of the $\left[\overset{\text{O}}{\parallel} \text{C}(\text{CH}_2)_m \underset{\underset{\text{R}^5}{|}}{\text{CH}}(\text{CH}_2)_n \underset{\underset{\text{R}^6}{|}}{\text{N}} \right]$

- subunits when $p = 2$;
 or a pharmaceutically acceptable salt thereof, with the proviso that R^1 , R^2 , and R^3 are
 10 not all hydrogen, further provided that R^1 , R^2 , and R^3 are not all


$\overset{\text{O}}{\parallel}$
 $-\left[\text{C}(\text{CH}_2)_m \underset{\underset{\text{R}^5}{|}}{\text{CH}}(\text{CH}_2)_n \underset{\underset{\text{R}^6}{|}}{\text{N}} \right]_p \text{CO}_2\text{R}^7$, and still further provided that t and u are not

both 0 when X is O or S.



15

35. A pharmaceutical composition for the use in treating transplantation rejection, host vs. graft disease, autoimmune diseases, and diseases of inflammation in a mammal which comprises, an immunosuppressive amount of a compound having the structure

- 41 -



wherein R^1 , R^2 , and R^3 are each, independently, hydrogen, or R^4 ;



10 R^5 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, $-(\text{CH}_2)_q\text{CO}_2\text{R}^8$, $-(\text{CH}_2)_r\text{NR}^9\text{CO}_2\text{R}^{10}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

15 R^6 and R^9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;

20 R^7 , R^8 , and R^{10} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy

- 42 -

of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

5 R^{11} and R^{12} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

10 X is $\begin{array}{c} R^{13} \\ | \\ -C- \\ | \\ R^{14} \end{array}$, O, or S;

R^{13} and R^{14} are each, independently, hydrogen or alkyl of 1-6 carbon atoms;

Y is CH or N;

m is 0 - 4;

n is 0 - 4;

15 p is 1 - 2;

q is 0 - 4;

r is 0 - 4;

t is 0 - 4;

u is 0 - 4;

wherein R^5 , R^6 , m , and n are independent in each of the $\begin{array}{c} O \\ || \\ [C(CH_2)_mCH(CH_2)_nN] \\ | \quad | \\ R^5 \quad R^6 \end{array}$

20 subunits when $p = 2$;


or a pharmaceutically acceptable salt thereof, with the proviso that R^1 , R^2 , and R^3 are not all hydrogen, further provided that R^1 , R^2 , and R^3 are not all

$\begin{array}{c} O \\ || \\ -[C(CH_2)_mCH(CH_2)_nN]_pCO_2R^7 \\ | \quad | \\ R^5 \quad R^6 \end{array}$, and still further provided that t and u are not


25 both 0 when X is O or S.

- 43 -

36. A pharmaceutical composition for the use in treating fungal infections, which comprises an antifungal amount of a compound having the structure



wherein R¹, R², and R³ are each, independently, hydrogen, or R⁴;




R⁵ is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, $-(CH_2)_qCO_2R^8$, $-(CH_2)_rNR^9CO_2R^{10}$, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

R⁶ and R⁹ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;

- 44 -

5 R^7 , R^8 , and R^{10} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;


10 R^{11} and R^{12} are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;



15 R^{13} and R^{14} are each, independently, hydrogen or alkyl of 1-6 carbon atoms;
 Y is CH or N;
 m is 0 - 4;
 n is 0 - 4;
 p is 1 - 2;
 q is 0 - 4;
20 r is 0 - 4;
 t is 0 - 4;
 u is 0 - 4;

wherein R^5 , R^6 , m , and n are independent in each of the
$$\begin{array}{c} \text{O} \\ || \\ [\text{C}(\text{CH}_2)_m \text{CH}(\text{CH}_2)_n \text{N}] \\ | \quad | \\ \text{R}^5 \quad \text{R}^6 \end{array}$$


subunits when $p = 2$;
or a pharmaceutically acceptable salt thereof, with the proviso that R^1 , R^2 , and R^3 are
25 not all hydrogen, further provided that R^1 , R^2 , and R^3 are not all





both 0 when X is O or S.

- 45 -

37. A process for preparing a compound of the formula



wherein R¹, R², and R³ are each, independently, hydrogen, or R⁴;



R⁵ is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms,

-(CH₂)ₑCO₂R⁸, -(CH₂)ᵣNR⁹CO₂R¹⁰, carbamylalkyl of 2-3 carbon atoms, aminoalkyl of 1-4 carbon atoms, hydroxyalkyl of 1-4 carbon atoms, guanylalkyl of 2-4 carbon atoms, mercaptoalkyl of 1-4 carbon atoms, alkylthioalkyl of 2-6 carbon atoms, indolylmethyl, hydroxyphenylmethyl, imidazolylmethyl or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

R⁶ and R⁹ are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aralkyl of 7-10 carbon atoms;

R⁷, R⁸, and R¹⁰ are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, fluorenylmethyl, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy

- 46 -

of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

R¹¹ and R¹² are each, independently, alkyl of 1-6 carbon atoms, aralkyl of 7-10 carbon atoms, or phenyl which is optionally mono-, di-, or tri-substituted with a substituent selected from alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydroxy, cyano, halo, nitro, carbalkoxy of 2-7 carbon atoms, trifluoromethyl, amino, or a carboxylic acid;

X is $\begin{array}{c} \text{R}^{13} \\ | \\ -\text{C}- \\ | \\ \text{R}^{14} \end{array}$, O, or S;

R¹³ and R¹⁴ are each, independently, hydrogen or alkyl of 1-6 carbon atoms;

Y is CH or N;

m is 0 - 4;

n is 0 - 4;

p is 1 - 2;

q is 0 - 4;

r is 0 - 4;

t is 0 - 4;

u is 0 - 4;

wherein R⁵, R⁶, m, and n are independent in each of the $\begin{array}{c} \text{O} \\ || \\ [\text{C}(\text{CH}_2)_m \text{CH}(\text{CH}_2)_n \text{N}] \\ | \quad | \\ \text{R}^5 \quad \text{R}^6 \end{array}$

subunits when p = 2;

or a pharmaceutically acceptable salt thereof, with the proviso that R¹, R², and R³ are not all hydrogen, further provided that R¹, R², and R³ are not all



$\begin{array}{c} \text{O} \\ || \\ -[\text{C}(\text{CH}_2)_m \text{CH}(\text{CH}_2)_n \text{N}]_p \text{CO}_2\text{R}^7 \\ | \quad | \\ \text{R}^5 \quad \text{R}^6 \end{array}$, and still further provided that t and u are not

both 0 when X is O or S;

which comprises (a) acylating rapamycin with an acylating agent or (b) sequentially

acylating rapamycin with one or more acylating agents, said acylating agent(s) being selected from acids of formula:

- 47 -



where Z is OH

or reactive derivatives thereof, if desired protecting any of 42, 31 and 14 positions of

5 rapamycin with an appropriate protecting group and removing said group as required,
and further if desired isolating the product as a pharmaceutically acceptable salt.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/06824

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl.5 C 07 D 498/18 C 07 K 5/06 A 61 K 31/395
A 61 K 37/02 //(C 07 D 498/18 C 07 D 311:00 C 07 D 275:00

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl.5 C 07 D 498/00 C 07 H 19/00 C 07 K 5/00
A 61 K 31/00 A 61 K 37/00

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0046661 (AYERST McKENNA AND HARRISON LTD) 3 March 1982, see the whole document, & US, A, 4316885 (cited in the application) -----	1,33-36
A	US,A,4650803 (VALENTINO J.S. AND KENNEDY P.E.) 17 March 1987, see the whole document (cited in the application) -----	1,33-36

¹⁰ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

13-12-1991


Date of Mailing of this International Search Report

16. 01. 92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

 Danielle van der Haas

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 33-34 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds
2. ☐ Claim numbers _____ because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:
3. ☐ Claim numbers _____ because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(b).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

ANNEX THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9106824
SA 52089

Int family members relating to the patent documents cited in the above-mentioned international search report.
obtained in the European Patent Office EDP file on 13/01/92
Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0046661	03-03-82	US-A- 4316885	23-02-82
		AT-T- E7920	15-06-84
		CA-A- 1159054	20-12-83
		JP-A- 57118586	23-07-82
US-A- 4650803	17-03-87	AU-B- 583439	27-04-89
		AU-A- 6608086	11-06-87
		CA-A- 1273920	11-09-90
		EP-A- 0227355	01-07-87
		EP-A- 0429436	29-05-91
		GB-A, B 2183647	10-06-87
		JP-A- 62215592	22-09-87

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.